McKesson Corporation and private equity firm Clayton Dubilier & Rice are approaching a final agreement to acquire Option Care Health in a transaction valued north of $5 billion, according to Financial Times reporting. The deal, which could close within weeks, represents one of the largest healthcare distribution plays in 2024 and marks McKesson's most aggressive move into at-home specialty infusion since it exited direct home care operations in 2018.
Option Care operates over 100 infusion centers across the United States and coordinates home-based therapies for roughly 100,000 patients annually, serving as the bridge between specialty pharmacies and patients receiving high-cost biologics, immunoglobulins, and oncology infusions. Revenue for the fiscal year ending March 2024 reached approximately $4.8 billion, with adjusted EBITDA margins running in the mid-to-high single digits—a spread that has tightened over the past eighteen months as payer scrutiny on site-of-care reimbursement intensified. McKesson's existing U.S. Pharmaceutical segment generated $190 billion in revenue last fiscal year, but gross margins have compressed to 2.9% as generic competition and rebate dynamics squeeze traditional distribution economics. Option Care's patient-level service model and direct infusion coordination offer a different margin profile, one that CD&R has reportedly modeled as durable under value-based care contracting.
This matters because the transaction signals a broader pivot among pharmaceutical distributors toward owning the last mile of specialty drug administration. McKesson already distributes to over 50,000 independent and chain pharmacies, but it has limited direct touchpoints with the subset of patients requiring infusion—where drug costs can exceed $50,000 per patient per year and adherence drives both clinical outcomes and manufacturer rebate structures. Acquiring Option Care places McKesson inside the reimbursement conversation with commercial payers and Medicare Advantage plans, which have been shifting infusion volumes from hospital outpatient departments to lower-cost settings at an accelerating rate. In calendar 2023, infusion site-of-care shifts saved payers an estimated $2.3 billion according to industry data, and health plans are now requiring prior authorization on over 80% of high-cost infusions. CD&R's co-investment suggests private equity sees structural tailwinds in outpatient infusion infrastructure, even as hospital systems attempt to retain these high-margin procedures.
Operators and allocators should watch for the form of consideration—whether McKesson finances this primarily with debt or structured partnership capital—as its current net debt sits near $6.7 billion and its leverage ratio is already elevated relative to peer distributors. CD&R's involvement likely means a minority stake structure or a joint venture vehicle, which would allow McKesson to consolidate Option Care's revenues while limiting balance sheet expansion. Expect disclosures on the transaction structure within two to three weeks if Financial Times timing holds. Additionally, monitor for regulatory filings under Hart-Scott-Rodino, particularly any second requests from the Federal Trade Commission, which has shown heightened scrutiny of vertical integration in pharmaceutical supply chains over the past eighteen months.
The deal's timing coincides with Medicare finalizing 2025 reimbursement rates for home infusion services—rates that are expected to increase by 3.1% for certain drug categories, a modest but stabilizing tailwind after two years of flat reimbursement.
The takeaway
McKesson's $5B+ Option Care bid with CD&R stakes last-mile infusion access as specialty margins compress and site-of-care economics reward at-home models.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.